The QualityStocks Daily Friday, May 26th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(VSTM) $1.0100 +125.55%

INO Market Report(ELEV) $5.0200 +66.78%

Tiny Gems(QBTS) $1.6700 +33.60%

The QualityStocks Daily Stock List

Verastem (VSTM)

MarketClub Analysis, MarketBeat, StockMarketWatch, StreetInsider, QualityStocks, BUYINS.NET, InvestorPlace, TraderPower, Marketbeat.com, Streetwise Reports, RedChip, TradersPro, TopStockAnalysts, Schaeffer's, The Street, Promotion Stock Secrets, Barchart, Penny Stocks Profile, The Online Investor, TheStockAdvisors, Jason Bond, Tiny Gems, Investing Futures and Dividend Opportunities reported earlier on Verastem (VSTM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Verastem Inc. (NASDAQ: VSTM) (FRA: 2VS) is a development-stage biopharmaceutical firm that is engaged in developing and commercializing therapies to improve the life of cancer patients.

The firm has its headquarters in Needham, Massachusetts and was founded in 2010, on August 4th by Christoph H. Westphal, Robert F. Weinberg, Eric S. Lander, Satish Jindal, Piyush Gupta, Michelle Dipp and Richard H. Aldrich. It serves healthcare professionals and patients in the U.S. and operates in the health care sector, under the biotech and pharma sub-industry.

The company is party to license agreements with Pfizer Inc. for researching, developing, manufacturing and commercializing products which contain Pfizer’s FAK inhibitors for prophylactic, diagnostic and therapeutic uses in people; and Chugai Pharmaceutical Co. Ltd for developing, commercializing and manufacturing products which contain VS-6766.

Its products include a formulation which is in its phase 2 trial to evaluate the safety of defactinib in combination with VS-6766, called RAMP 2020. The formulation is used in patients with KRAS mutant non-small cell lung cancer. Defactinib is an oral small molecule inhibitor of FAK (focal adhesion kinase). In addition, the company is also develops RAMP 201 to evaluate the safety and effectiveness of VS-6766 in combination with an oral small molecule inhibitor. This is in addition to developing VS-6766, a dual RAF (rapidly accelerate fibrosarcoma) MEK (mitogen-activated protein kinase) inhibitor, which blocks RAF’s ability to phosphorylate MEK as well as blocking MEK kinase activity.

The company recently received Breakthrough Therapy designation for its VS0-6766 candidate from the FDA. This will allow them to possibly bring a new therapy to the market, which will not only benefit the patients with low-grade serous ovarian cancer but also encourage more investments into the firm.

Verastem (VSTM), closed Friday's trading session at $1.01, up 125.5471%, on 84,076,159 volume. The average volume for the last 3 months is 5.772M and the stock's 52-week low/high is $0.2895/$1.47.

Bright Health Group (BHG)

QualityStocks, MarketBeat, Trades Of The Day, Daily Trade Alert, Schaeffer's and Early Bird reported earlier on Bright Health Group (BHG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bright Health Group Inc. (NYSE: BHG) is an integrated care delivery firm that is focused on the delivery and financing of health insurance plans.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 2015. Prior to its name change in February 2021, the firm was known as Bright Health Inc. It operates as part of the insurance carriers industry. The firm has seven firms in its corporate family and serves consumers in the United States.

The company aligns the best local resources in healthcare delivery with the financing of care, which helps lower costs, decrease systemic waste, optimize clinical outcomes and drive superior consumer experience. It generates revenue from income from investments as well as premiums, which include fee-for-service provider revenue received from payers and consumers, and value-based provider revenue.

The enterprise operates through the Bright Health Care and NeueHealth segments. Through the former segment, it provides commercial health plan products and Medicare products to roughly 620,000 consumers in 199 markets and fourteen states. The enterprise, through its latter segment, delivers high-quality in-person and virtual clinical care to about 75,000 patients via its 61 affiliated risk-bearing primary care clinics. In addition to this, it offers services through Care Partners, a network of hospitals, clinics and doctors.

The company has a strategic investment with Cigna Ventures, which brings deep healthcare expertise that complements the company’s mission of expanding access to affordable and quality healthcare. This move will also bring in more investors into the company as well as extend their consumer reach, which will be good for its growth.

Bright Health Group (BHG), closed Friday's trading session at $11.77, up 45.8488%, on 5,772,040 volume. The average volume for the last 3 months is 66.827M and the stock's 52-week low/high is $7.57/$13728.00.

Elevation Oncology (ELEV)

Actual Gains, QualityStocks, PennyStockRumors.net, OTCPicks, VIP STOCK ALERTS, Buzz Stocks, FeedBlitz, HEROSTOCKS, INO Market Report, Liquid Pennies, Otcstockexchange, Money Wealth Matters, Stock Exploder, The Night Owl, WhisperFromWallStreet, PennyTrader Publisher, Stockhunter.us, SmallCapStockPlays, Stock Brain and MarketBeat reported earlier on Elevation Oncology (ELEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elevation Oncology Inc. (NASDAQ: ELEV) is a clinical-stage biopharmaceutical firm that is engaged in the development of therapeutics for treating cancer in genomically-defined patient populations.

The firm has its headquarters in New York and was incorporated in 2019 by Shawn M. Leland. It serves consumers in the United States.

The company’s objective is to introduce new targeted therapies for patients with cancer as well as illuminate what the company is doing to create a future where every patient can receive care built around targeting their unique tumor drivers and understanding. This will be done by having every tumor’s unique genomic test result matched with a purpose-built precision medicine that will allow the use of individualized treatment plans for patients.

The enterprise’s formulations identify and target inhibition of tumor-specific drive alterations. Its product portfolio comprises of an anti-HER3 monoclonal antibody dubbed seribantumab, which is undergoing a phase 2 Crestone trial evaluating its effectiveness in treating advanced solid tumors that harbor neuregulin-1 fusions (NRG1 fusions).The NRG1 gene fusions are rare genomic alterations which combine NRG1 with other partner proteins to create a chimeric NRG1 fusion protein. These fusions have been identified in a variety of solid tumors, including cholangio carcinomas, neuroendocrine, colorectal, ovarian, breast, gallbladder, pancreatic, lung and sarcomas.

The firm is focused on making progress on its mission to bring purpose-built medicines to patients suffering from genomically defined cancers. The success of their formulations will not only address unmet needs in patients but also bring in more investments into the firm.

Elevation Oncology (ELEV), closed Friday's trading session at $5.02, up 66.7774%, on 66,827,008 volume. The average volume for the last 3 months is 10,696 and the stock's 52-week low/high is $0.7229/$5.89.

Bitdeer Technologies (BTDR)

We reported earlier on Bitdeer Technologies (BTDR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bitdeer Technologies Holding Co. (NASDAQ: BTDR) is a technology firm that is engaged in the provision of cryptocurrency mining solutions.

The firm has its headquarters in Singapore. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in the United States and Norway.

The company’s major business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. It handles complex processes involved in mining, such as miner procurement, transport logistics, mining datacenter design and construction, and mining machine management and daily operations. The company operates 5 proprietary mining datacenters in the United States and Norway.

The enterprise’s proprietary mining refers to cryptocurrency mining for its own account, which allows it to directly capture the high appreciation potential of cryptocurrency. It offers two types of hash rate sharing solutions, namely Cloud Hash Rate and Hash Rate Marketplace. Through Cloud Hash Rate, the firm sells its hash rate to customers. It offers hash rate subscription plans at fixed price and share mining income with them under certain arrangements. The company's hosting services offer customers mining machine hosting solutions encompassing deployment, maintenance, and management services for cryptocurrency mining.

The company, which recently entered into a partnership agreement with Druk Holding and Investments, recently announced its latest financial results with its CEO noting that they were focused on expanding their global footprint through partnerships. This will, in turn, open the company up to new growth and investment opportunities.

Bitdeer Technologies (BTDR), closed Friday's trading session at $5.12, up 3.854%, on 10,696 volume. The average volume for the last 3 months is 1,012 and the stock's 52-week low/high is $4.63/$9.70.

Kuber Resources (KUBR)

We reported earlier on Kuber Resources (KUBR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kuber Resources Corporation (OTC: KUBR) is a company focused on distributing and trading tea products in Hong Kong.

The firm has its headquarters in Hong Kong and was incorporated in 1998, on January 29th by Tsun Sin Man. Prior to its name change in November 2022, the firm was known as Uonlive Corp. It operates as part of the farm products industry, under the consumer defensive sector. The firm serves consumers in Hong Kong as well as in the United States and the People’s Republic of China.

The company’s purpose is to connect people. It focuses on tea planting and sales, research, and development. The company’s business scope includes partnering with tea plantations for tea production, such as Dongguan Gongxiang Tea Food Company Ltd, and sales as well as agricultural tourism. Its production is focused primarily on pu-er tea. The company’s tea plantation partners offer a range of tea drinks. The main product being sold is Yunnan Chi Tse Beeng Cha, which is a type of pu-er tea. Its products are offered via its managed stores. The product is produced, packaged, and ready for consumption by its tea plantation partners in China. It also imports precious metal commodities, such as tin ore. This is in addition to developing a physical venue for executives to meet and network.

The enterprise remains focused on expanding into international trade and consulting, which may extend its consumer reach and bring in additional revenues into the firm. This is in addition to creating value for its shareholders.

Kuber Resources (KUBR), closed Friday's trading session at $4.3, off by 2.2727%, on 1,012 volume. The average volume for the last 3 months is 356,869 and the stock's 52-week low/high is $1.05/$6.00.

City Office REIT (CIO)

InvestorPlace, MarketBeat, The Online Investor, The Street Report, StreetInsider, Kiplinger Today, Marketbeat.com, Zacks, Barchart, Market Intelligence Center, QualityStocks, Daily Trade Alert, Market Intelligence Center Alert, Money Morning, Schaeffer's and BUYINS.NET reported earlier on City Office REIT (CIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

City Office REIT Inc. (NYSE: CIO) (FRA: 5QV) is a real estate investment trust that invests in high-quality office properties in 18-hour cities with strong economic fundamentals, primarily in Western and Southern United States.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2013, on November 26th. It operates as part of the REIT-Office industry, under the real estate sector. The firm mainly serves consumers in Canada and the United States.

The company is focused on acquiring, owning and operating office properties located predominantly in Sun Belt markets. Its markets display nation-leading employment and population growth trends, feature high-quality urban living experiences in amenitized settings and offer outsized return and growth potential for their investments. It owns about 60 office buildings with a total of roughly 6 million ft2 of net rentable area (NRA) in the metropolitan areas of Dallas, Orlando, Denver, Phoenix, Portland, Raleigh, Seattle, Tampa and San Diego. The company's properties include 190 Office Center, The Terraces, 2525 McKinnon, Block 23, Pima Center, Canyon Park, AmberGlen, Cascade Station, Bloc 83, Greenwood Blvd, Central Fairwinds, Mission City, Florida Research Park, Denver Tech, Circle Point, Superior Pointe, Intellicenter, City Center, Park Tower, Papago Tech, The Quad, Camelback Square, 5090 N 40th St, SanTan and Carillon Point.

The enterprise recently announced its latest financial results, with its CEO noting that they remained focused on better positioning the firm for long-term success, growing their portfolio and generating value for its shareholders.

City Office REIT (CIO), closed Friday's trading session at $4.6, up 1.5453%, on 356,869 volume. The average volume for the last 3 months is 13,726 and the stock's 52-week low/high is $4.03/$14.24.

Osino Resources (OSIIF)

We reported earlier on Osino Resources (OSIIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Osino Resources Corp (OTCQX: OSIIF) (CVE: OSI) (FRA: RSRI) is a mineral exploration firm that is focused on exploring for, acquiring and developing gold mining properties in Namibia.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2012, on June 5th by Alan Friedman and Heye Daun. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers in Namibia, South Africa and Canada.

The company holds various early-stage gold exploration projects in the Republic of Namibia. Its flagship project is the Twin Hills project that comprises of 11 licenses which cover 153,206 hectares located in Central Namibia. The Osino Gold Project is located in central Namibia in the area known as the Central Plateau. The project area extends from about 150 km northwest to 300 km north-northeast of the capital city of Namibia, Windhoek. It owns 100% of the Namibian prospecting license 3195 covering 19,969 hectares located roughly 130 km northwest of company’s Twin Hills Gold Project in Namibia. The Otjiwarongo Regional Exploration project consists of six licenses with a surface area in excess of 3,000 km2 situated in central Namibia. The Karibib District Project is held through 14 licenses comprising approximately 156,000 hectares.

The enterprise, which recently announced a new lithium discovery, remains focused on advancing its exploration and drilling programs and begin production. This may, in turn, encourage more investments into the firm while bringing in additional revenues.

Osino Resources (OSIIF), closed Friday's trading session at $0.83345, off by 2.372%, on 13,726 volume. The average volume for the last 3 months is 1.747M and the stock's 52-week low/high is $0.38/$0.9359.

W&T Offshore (WTI)

MarketClub Analysis, Zacks, TopStockAnalysts, MarketBeat, Profit Confidential, StocksEarning, CustomerService, StreetInsider, The Growth Stock Wire, BUYINS.NET, Marketbeat.com, Wall Street Resources, Schaeffer's, Investing Daily, Daily Trade Alert, TradersPro, Trades Of The Day, StreetAuthority Daily, Uncommon Wisdom, Money Morning, InvestorPlace, ProfitableTrading, Investopedia, StockMarketWatch, WStreet Market Commentary, The Street, The Street Report, Hit and Run Candle Sticks, QualityStocks, Daily Dividends, Investors Alley, Top Secret Stocks, OilAndEnergyInvestor, Louis Navellier, Wall Street Daily, Kiplinger Today, Jason Bond, TradingMarkets, Turn Key Oil, Investing Lab, Energy and Capital, Early Bird, Wall Street Mover, Daily Markets, Daily Gains Letter, ChartPoppers, Cabot Wealth, Energy Capital Research Group, PowerRatings Stocks, Street Insider, Technical Speculator, Stocks To Watch, The Online Investor, Stock Market Watch, Sling-Shot-Stocks, Shah's Insights & Indictments, Trading Markets, The Tycoon Report, TopPennyStockMovers, Penny Sleuth, Penny Detectives, OTCJournal, Motley Fool Hidden Gems, Top Pros' Top Picks, MicrocapAlliance, Taipan Daily and The Stock Enthusiast reported earlier on W&T Offshore (WTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

W&T Offshore, Inc. (NYSE: WTI) (FRA: UWV) is an independent oil and natural gas producer that is focused on exploring for, acquiring and developing oil and natural gas properties in the Gulf of Mexico.

The firm has its headquarters in Houston, Texas and was incorporated in 1983 by Tracy W. Krohn. It operates as part of the oil and gas E&P industry, under the energy sector. The firm primarily serves consumers in the United States.

The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of its revenue, with natural gas accounting for a much smaller portion. The company’s wholly owned subsidiaries include Aquasition Energy, LLC, Aquasition, LLC, Aquasition II, LLC, Aquasition III, LLC, Aquasition IV, LLC, Aquasition V, LLC, Green Hell, LLC, Seaquester, LLC, Seaquestration, LLC and W & T Energy VI, LLC.

The enterprise has an interest in over 47 offshore producing fields in federal and state waters (45 fields producing and two fields capable of producing, which include 39 fields in federal waters and eight in state waters). It has under lease roughly 625,000 gross acres spanning across the outer continental shelf off the coasts of Louisiana, Texas, Mississippi and Alabama, with approximately 8,000 gross acres in Alabama State waters, 458,000 gross acres on the conventional shelf and approximately 159,000 gross acres in the deep water.

The firm recently released its latest financial results, with its CEO noting that they remained focused on taking advantage of potential acquisition, delivering on their strategic vision and enhancing shareholder value.

W&T Offshore (WTI), closed Friday's trading session at $4.06, off by 0.97561%, on 1,746,682 volume. The average volume for the last 3 months is 247,712 and the stock's 52-week low/high is $3.57/$9.16.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Apart from brief research that was carried out in the 1960s, scientists don’t know a lot about the underlying mechanisms that allow psychedelics to deliver their mental health benefits. To help bridge this crucial knowledge gap, several institutions have teamed up to survey the Canadian public on psychedelics.

Called the Canadian Psychedelic Survey (CPS), the poll was cosponsored by Psygen Industries, SABI Mind and MAPS PBC, and designed with the aid of academic researchers from top universities and clinicians.  The 655-question survey was mainly concerned with collecting data on the characteristics of psychedelics, their patterns of use and public access to hallucinogens.

It specifically focused on DMT, LSD, MDMA, Salvia divinorum, mescaline, psilocybin, ibogaine and ayahuasca. These are among the many psychedelic drugs that have exhibited medical potential against mental health disorders in initial studies and based on anecdotal evidence.

The researchers wanted to collect real-world data on the way Canadians use psychedelics, something clinicians and scientists across the world are sorely missing. They collected data on patterns of therapeutic and recreational use and the connection between hallucinogens such as LSD to mental health, headaches, mindfulness and the use of other drugs.

Aside from helping to alleviate the symptoms of mental conditions, such as post-traumatic stress disorder and treatment-resistant depression, psychedelics have also shown that they can help patients to address substance use disorders.

After tabulating their results, the researchers found that LSD, MDMA and psilocybin were the most popular psychedelics. Survey results show that 92.3% of participants had used psilocybin at least once and 59.1% had consumed the psychedelic within the past year. On the other hand, MDMA and LSD trailed the most popular psychedelics with slightly more than 60% using them once and 25 percent using them in the past year.

Ibogaine, which can act as a mild stimulant in small doses and help to reduce opioid withdrawal symptoms in larger doses, was the least-used psychedelic with only 2.3% using it at least once and 1% consuming it in the past 23 months. In addition, 76.5% of the participants reported using psychedelics for fun, 73.3% used them for self-exploration, 60.5% for personal growth, and 62.4% to improve their mental well-being.

The survey also showed that 82% of the participant pool said that their psychedelic experience resulted in “lifetime intense positive experiences.” Only 15.2% said they accessed psychedelics through the black market or a street dealer while 62.8% gained access via a friend or acquaintance, and 48.1% reported getting psychedelics through the internet sometimes. More than 56% reported that they preferred to get psychedelics in a physical brick-and-mortar shop, 50.6% would rather gain access through medical professionals or clinics, and 64% of the participant pool preferred purchasing psychedelics online if the option was available.

The findings of this survey may give psychedelics startups such as Seelos Therapeutics Inc. (NASDAQ: SEEL) a few things to think about as they adapt their long-term strategies to the changing realities of the rapidly growing market for psychedelics-based treatments.

Seelos Therapeutics Inc. (SEEL), closed Friday's trading session at $0.9249, up 2.1876%, on 247,712 volume. The average volume for the last 3 months is 792,080 and the stock's 52-week low/high is $0.5751/$1.52.

Arch Resources Inc. (ARCH)

InvestorPlace, Zacks, MarketBeat, QualityStocks, The Online Investor, MarketClub Analysis, TradersPro, Kiplinger Today, The Street, Daily Wealth, DividendStocks, Schaeffer's, Investors Alley, StreetAuthority Daily, InvestorGuide, Cabot Wealth, Daily Trade Alert, Early Bird, Investing Daily, Uncommon Wisdom, Barchart, Trades Of The Day, StreetInsider and FreeRealTime reported earlier on Arch Resources Inc. (ARCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Records published by the Kommersant business daily show that Russia’s coal exports have increased by nearly 20% in the first quarter of 2023. The publication reported that exports of all types of Russian coal from January to April had gone up by 18% following an uptick in coal exports in March.

Russia exported 69.9 million tons of coal over the sea in Q1 2023, with shipments through the usually profitable ports in the south and Far East decreasing due to competition from other kinds of cargo.

The Kremlin has been subject to extensive sanctions since early 2022 from most Western countries in response to its unprovoked invasion of Ukraine. Key Russian exports including coal, oil and fertilizers, have been sanctioned by numerous countries, and Russia itself cut natural gas exports to the rest of Europe in retaliation for the sanctions.

However, Russia has been able to keep its export numbers up by selling cheaply to countries that haven’t taken part in sanctions against the Kremlin, such as China and India. The recently released data shows that despite the sanctions Russia has faced regarding coal exports, it is still finding ways to get millions of tons of coal to its trading partners via the sea.

Kommersant said that Russia increased coal exports through the sea after it redirected its exports to Asia in the wake of European countries stopping purchases of the Kremlin’s energy. The European Union, one of the largest consumers of Russian coal exports, placed an embargo on the country’s coal last August.

Since 2022, the publication reports, Russia has redirected a whopping 140 million tons of coal to Asia through sea routes.

A report from Bloomberg stated that Asia’s increasing reliance on Russian coal was due to sweltering heat levels that have forced Asian countries to spend more on air conditioning and lighting. With 2023 predicted to be the hottest year on record in terms of global warming, Asian countries will most likely stick to relatively cheap Russian energy for the foreseeable future.

Kommersant noted that competition from railway and other cargo was placing pressure on seaborne shipments, stating that exporting coal often presents miners with plenty of financial difficulties. The publication said that Russian Railways would have to take steps to increase its railway capacity toward both the east and south to ease the pressure on sea shipments.

This additional capacity would be extremely beneficial as Russia will likely have trouble maintaining coal shipments via the sea due to the increasing expenses and costs compared to rail.

The reality that Russia is still exporting coal despite the international sanctions against it just goes to show how much demand still exists for this source of energy. It also explains why coal extraction enterprises such as Arch Resources Inc. (NYSE: ARCH) still have a role to play in helping different countries meet their energy needs even if coal has fallen out of favor due to its massive greenhouse gas emissions.

Arch Resources Inc. (ARCH), closed Friday's trading session at $107.96, off by 3.305%, on 792,080 volume. The average volume for the last 3 months is 963,081 and the stock's 52-week low/high is $109.3145/$180.10.

Novo Nordisk (NVO)

Kiplinger Today, InvestorPlace, MarketClub Analysis, MarketBeat, The Online Investor, Louis Navellier, Daily Trade Alert, The Street, Zacks, Trades Of The Day, TipRanks, SmarTrend Newsletters, Top Pros' Top Picks, Barchart, INO.com Market Report, StreetAuthority Daily, Marketbeat.com, StocksEarning, TheStockAdvisors, TradersPro, StreetInsider, Early Bird, TopStockAnalysts, Investor Guide, Schaeffer's, Streetwise Reports, Market Authority, Stock Gumshoe, Street Insider, Daily Markets, Investopedia, Greenbackers, BUYINS.NET, Forbes, FeedBlitz, Daily Profit, CNBC Breaking News, Daily Stocks, Daily Wealth, Cabot Wealth, Investing Lab, InvestmentHouse, Wall Street Daily, Investors Alley, Uncommon Wisdom, Market Intelligence Center Alert, Money Morning, Navellier Growth, QualityStocks, The Best Newsletters, The Growth Stock Wire, The Motley Fool, TheStockAdvisor and Market FN reported earlier on Novo Nordisk (NVO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Novo Nordisk (NYSE: NVO) was featured in a recent analysis report that discussed rocketing mentions of the company’s Ozempic drug (+86). “Ozempic (made by Novo Nordisk) currently holds a massive brand recognition lead when it comes to mention volume vs. other established brand names,” reads the report, written by LikeFolio Founder Andy Swan. The publication also mentions...

To read the full report and view the infographic, please visit https://ibn.fm/90nZ5

About Novo Nordisk

Novo Nordisk is a global health care company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Its purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. Novo Nordisk does so by pioneering scientific breakthroughs, expanding access to its medicines and working to prevent and ultimately cure the diseases it treats. Novo Nordisk employs more than 55,000 people in 80 offices around the world and markets its products in 170 countries.

Novo Nordisk (NVO), closed Friday's trading session at $162.97, up 0.326274%, on 963,081 volume. The average volume for the last 3 months is 437,555 and the stock's 52-week low/high is $95.02/$172.97.

Bright Green Corporation (BGXX)

QualityStocks, The Stock Dork, Money Wealth Matters, MarketClub Analysis, InvestorsUnderground and Early Bird reported earlier on Bright Green Corporation (BGXX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bright Green (NASDAQ: BGXX) is one of the few companies selected by the U.S. government to grow, manufacture and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. The company recently announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,684,210 shares of common stock and warrants to purchase up to 3,684,210 shares of common stock, at a purchase price of $0.95 per share and accompanying warrant. Bright Green expects approximately $3.5 million in gross proceeds from the private placement. EF Hutton, division of Benchmark Investments LLC, is acting as the exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/8gGpu

About Bright Green Corporation

Bright Green is one of the very few companies authorized by the U.S. government to grow, manufacture and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Bright Green’s registration by the U.S. Drug Enforcement Administration gives it the opportunity to advance its vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.BrightGreen.us.

Bright Green Corporation (BGXX), closed Friday's trading session at $0.82, off by 5.6821%, on 437,555 volume. The average volume for the last 3 months is 836,247 and the stock's 52-week low/high is $0.35/$10.61.

The QualityStocks Company Corner

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting on positive data gathered from the phase 1 portion of its Acclaim-1 clinical trial. The trial is designed to evaluate the company's proprietary lead product candidate, REQORSA(R) Immunogene Therapy, in combination with Tagrisso(R) in the treatment of late-stage non-small cell lung cancer ("NSCLC"). The results are being published in an abstract at the 2023 American Society of Clinical Oncology ("ASCO") annual meeting, held on June 2–6, 2023, in Chicago. According to the announcement, the results demonstrate that the combination of REQORSA and Tagrisso was well tolerated at all three dose levels evaluated in the study; in addition, encouraging evidence of efficacy was observed. "We are thrilled to have our abstract, which reports positive results from the phase 1 portion of our Acclaim-1 clinical trial, published at the ASCO annual meeting," said Genprex chief medical officer Mark Berger in the press release. "We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed, and we believe this data will support our advancement to the phase 2 portion of the clinical trial."

To view the full press release, visit https://ibn.fm/6utcv

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Friday's trading session at $0.89, up 4.7059%, on 836,247 volume. The average volume for the last 3 months is 101,885 and the stock's 52-week low/high is $0.7225/$2.67.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria held its virtual 2023 Annual Shareholders meeting on May 9, 2023

On the agenda were the election of six director nominees, the ratification of the appointment of the company's independent registered public accounting firm, and the approval of a one-time repricing of specific issued stock options, among others

All items presented received approval, with the highest approval percentage standing at 97.6% and the lowest at 63.1%

The meeting presented an opportunity for Lexaria to evaluate areas of expertise that would provide additional benefits to the company and its shareholders while also adding diversity to its board

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, on May 9 held its 2023 Annual Shareholder Meeting, in which 3,372,024 shares, constituting 56.3% of the company's issued share capital, were represented.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $0.7836, up 4.48%, on 101,885 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.67/$.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, today announced a new deployment at a storage facility in Napa, California. The announcement reads, "Storage facilities are generally safe, but they are often targets for break-ins leaving personal possessions and commercially stored items at risk. Knightscope's K5 Autonomous Security Robot (‘ASR') will patrol the storage facility to help mitigate risk and elevate the protection offered to tenants that choose to store their belongings. "Other storage facilities and businesses looking for a long-term public safety technology solution are encouraged to book a discovery call or demonstration now at www.knightscope.com/discover to learn more about Knightscope's Autonomous Security Robots and blue light emergency communication systems."

To view the full press release, visit https://ibn.fm/ZpOIS

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Friday's trading session at $0.4189, up 2.2955%, on 1,358,245 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3988/$4.5197.

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Atopic dermatitis or eczema is a topical condition that causes patches of inflamed, dry and itchy skin. While it typically starts in childhood and becomes milder with age, some people can develop eczema as adults. Eczema can occur due to a wide variety of reasons including low humidity, dry weather, skin products, detergents and soaps, stress and even certain fabrics. Genetics also makes some people more likely to have eczema, and those individuals have a higher chance of experiencing flare-ups in response to triggers such as skin products, hormonal changes and allergens. Although it is irritating, atopic dermatitis is not life threatening and cannot be transmitted to other people. British Skin Foundation spokesperson and consultant dermatologist Dr. Derrick Phillips advises adults to see a doctor or dermatologist as soon as possible if they experience a sudden eczema flare-up to receive appropriate treatment. Those eczema treatments could include products from several companies, including Jupiter Wellness Inc. (NASDAQ: JUPW).

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

  • Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
  • Psoriasis & VitiligoPhotocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
  • Jellyfish Protection SunscreenNoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
  • EczemaJW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
  • BurnsJW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
  • Cold SoresJW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
  • Sexual WellnessJW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • COVID-19-Induced TinnitusJW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Last Friday night, all across Vancouver, British Columbia, cannabis retail shops were taking the coverings off of their windows. This was after the government altered the law in response to a spike in cannabis store robberies in the province. The move is meant to protect both customers and sellers. Until recently, the opaque film window coverings were a condition of cannabis retail shop provincial licensing, ensuring that none of the goods were visible from the outside; the approach was an attempt to keep minors away from cannabis products. While some stores have roomy interiors or stylish furnishings that deftly cover the material, those can be pricey solutions; hence, the majority of stores choose to use frosted windows. The window covering option has creates risks for personnel and customers who are inside because visibility and situational awareness are greatly reduced; the installation of surveillance cameras by many stores hasn't helped. This caused marijuana sellers to convey their safety worries to the government. With security concerns rising in most jurisdictions where marijuana sales are legal, many companies such as Advanced Container Technologies Inc. (OTC: ACTX) will be following how the authorities respond to contain the threats these businesses face. This is because what happens to marijuana companies can have a domino-effect on other industries that are interlinked with the marijuana space.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.2568, up 328%, on 200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.032/$1.00.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

NextPlat inks deal to provide American businesses easy access to Chinese consumer market

E-Commerce Development Program in collaboration with  Tmall Global announced at Miami event

Tmall Global e-commerce platform will provide NextPlat customers simple turnkey solution to sell products to the Chinese consumer market

First in a series of new e-commerce development programs designed to provide US businesses swift, easy e-commerce access to new international customers

April 24, 2023, was a great day in Miami for NextPlat (NASDAQ: NXPL, NXPLW) and U.S. businesses eager to expand their e-commerce efforts and market goods to the multitrillion-dollar Chinese consumer market. In collaboration with Alibaba's Tmall Global, NextPlat formally introduced the launch of its new Florida E-Commerce Development Program (https://ibn.fm/UZGwH), the first in a series of new e-commerce development programs designed to provide U.S. businesses swift, easy e-commerce access to new customers in the Chinese market.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Friday's trading session at $2.18, off by 3.5398%, on 99,912 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, was recently featured in a corporate update by Focus Communications. Eloro's Executive VP of Exploration, Bill Pearson, was a guest of the program and discussed the company's latest drill results from its ongoing drilling activity within the Santa Barbara High-Grade Zone and provided guidance on its next steps. "Since acquiring an option to purchase a 100% interest in the highly prospective Iska Iska Property, which hosts a major silver-tin polymetallic porphyry-epithermal complex, Eloro Resources has carried out over 85,000 metres of diamond drilling activity across 122 holes between September 2020 and November 2022," reads a recent article. "Initial findings have been promising; as Pearson explained, holes DSB-50, DSB-51 and DSB-52, the southernmost holes tested to determine the potential south-southeastern extension of the high-grade one at Santa Barbara, each returned well mineralized intersections over 100m core length. Along with noting that the drill holes explored within the Santa Barbara Deposit's south-southeastern extension have been notable rich in zinc values, Pearson also suggested that the three holes effectively expanded the strike extent of the Santa Barbara High-Grade Zone to between 1,100m and 1,200m, thus significantly expanding the potential pittable resource. . . With drilling and geophysical surveys now taking place to explore the potential major tin porphyry target south of Iska Iska as well as on the Casiterita property to the southwest, Pearson reaffirmed his confidence that Eloro Resources had the ‘potential to [uncover] two world-class deposits' with ‘one likely in the bank at Santa Barbara.'"

To view the full article, visit https://ibn.fm/Oh4Vj

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.

Projects

Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Friday's trading session at $2.032, off by 0.878049%, on 19,910 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.02/$3.40.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

According to a senior federal health official, cannabis products must be controlled as states continue to legalize marijuana. Nora Volkow, director of NIDA, stated that while it would be ideal if states took their time enacting reform, the reality is that they are enacting reform and people need to know what they can do to lessen negative impacts. Volkow asserted that it is crucial to regulate the sale of products and inform the public about potential negative consequences. The official's remarks are noteworthy because, although she did not specifically demand federal reform, such a shift in policy would be required to impose controls on interstate marijuana sales on a national level. Volkow also acknowledged new studies looking into a potential connection between marijuana usage and an increased risk of psychosis, noting that regrettably, cannabis may not be as innocuous as it appears. Although Volkow cautioned against the potential risk of heavy use of marijuana products with high potency, she stated in 2021 that she hasn't yet seen proof that occasional marijuana usage by adults is detrimental. Given the concerns being expressed about the high potency of the marijuana that is currently available, companies seeking to avail standardized medicines from cannabis, such as IGC Pharma Inc. (NYSE American: IGC), deserve to be applauded because those formulations, once approved, can offer users a safe way to benefit from cannabis compounds without exposing themselves to any potential risks associated with consuming high-potency marijuana while addressing their medical needs.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Friday's trading session at $0.2963, off by 4.4194%, on 132,629 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.8432.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.1, up 17.2058%, on 603,985 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.051/$0.17.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Friday's trading session at $0.0002, up 33.3333%, on 2,270,315 volume. The average volume for the last 3 months is 2.27M and the stock's 52-week low/high is $0.000001/$0.0004.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

chart

Utopia VR

The QualityStocks Daily Newsletter would like to spotlight Utopia VR

Utopia VR is one of the world’s first ‘Metaverse-As-A-Service’ solutions for business. The company’s hosted and managed subscription software provides businesses a low barrier to entry, browser-based, device agnostic platform where they can manage their own private 3D metaverse meeting spaces. Users can host and attend Zoom-like virtual meetings in lifelike virtual reality – with no software downloads – engaging their audiences in a more collaborative and fun way.

Utopia VR has many technology and privacy advantages over solutions built on other metaverse marketplaces such as Horizon Worlds (META) or Decentraland. Utopia VR works on all devices – PC, mobile and virtual reality headsets – whereas many competitors only work in VR or on PC.

Utopia VR is headquartered in Kelowna, B.C.

Products

Utopia VR’s The Metaverse for Everyone™ is a one-click, web-based, avatar-driven, mobile-friendly audio- and video-conferencing platform that utilizes innovative 3D web technology. Utopia VR’s virtual platform works on digital devices including PCs, mobile phones and VR headsets such as Oculus Quest or HTC Vive. No software or proprietary hardware is needed.

 

Users navigate through the various VRoom environments by using avatars. Users can walk, talk and sit – just like they do in the real world. A user’s avatar can be controlled with a computer keyboard, smartphone or virtual reality headsets. Text chat, voice and video is ever-present and used to communicate with others in the VRoom. For important meetings and presentations, users can also import audio, video, 2D art and images, animated 3D objects, PDF files and their favorite NFTs by simply dragging and dropping files into a VRoom or pasting a video link from supported media platforms.

Organizations that have an existing website can transition their digital assets, including text, images, video, PDFs, slideshows and more, to VRoom environments with a simple copy and paste. This will allow their customers and audiences to experience their brand in a whole new, immersive environment.
Utopia VR’s mobile app enables users to personalize their own 3D environments and then schedule business meetings or social meetups in seconds through a proprietary link management system. The app is available for iPhone and iPad users. The company’s website mirrors the app, which means users can access Utopia VR directly from a PC, laptop, tablet, or VR headset without downloading the app.

Market Outlook

Regarded as the next iteration of the internet, the metaverse is a virtual space where the physical and digital worlds coexist and interact, encompassing virtual reality, augmented reality, extended reality and mixed reality, as well as making use of artificial intelligence and other technologies.

Data consolidator Statista estimated that the global metaverse market size stood at $38.85 billion in 2021 and projected the market would grow to be worth $47.48 billion in 2022. From there, Statista forecasts the value of the metaverse market will explode to reach $678.8 billion by 2030, achieving a CAGR of more than 39% over the period.

The metaverse could create $5 trillion in opportunity by 2030, according to McKinsey & Company.

Management Team

Stuart Gray, President, Co-Founder and director of Utopia VR, has been an officer and director for both private and publicly traded companies and has led public offerings for junior listed companies that have gone on to realize multibillion-dollar market valuations. He previously was a consultant and quarterbacked taking eXp World Holdings Inc. (NASDAQ: EXPI) public. eXp is a disruptive, no bricks and mortar, real estate brokerage firm with 85,000 agents worldwide using its virtual, software-based, metaverse platform for closing transactions, training and events.

Cory Braden, CTO and director of Utopia VR, is a forward-thinking strategic leader with over 20 years of experience in delivering software as a service. Recognized for a positive leadership style and excellent communication skills, he is well-versed in user experience, complex application architectures, cloud infrastructure and management of high-performance teams.

Terry Woloszyn, VP of Sales and Advisory at Utopia VR, brings vast technical and sales experience to the company. Before joining Utopia VR, he conceived and launched a data security startup and graduated from two startup accelerator programs. He has personally raised $20 million in equity venture funding.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.